Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1858-1867

  Nabholtz, J M ^a   Gelmon, K ^a   Bontenbal, M ^a   Spielmann, M ^a   Catimel, G ^a   Conte, P ^a   Klaassen, U ^a   Namer, M ^a   Bonneterre, J ^a   Fumoleau, P ^a   Winograd, B ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 8944245005     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1858     Document Type: Article

References (11)

1. Harris JR, Morrow M, Bonadonna G: Cancer of the breast, in DeVita VT, Hellmann S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, pp 1264-1332
2. Coates A, Gebski V, Stat M, et al: Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317:1490-1495, 1987
3. Henderson IC: Chemotherapy of advanced disease, in Harris JR, Henderson IC, Hellmann S, et al (eds): Breast Disease. Philadelphia, PA, Lippincott, 1987, pp 428-479
4. Clavel M, Catimel G: Breast cancer: Chemotherapy in the treatment of advanced disease. Eur J Cancer 29A:598-604, 1993
5. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of paclitaxel, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
6. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
7. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
9. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
10. Lenderking WR, Gelber RD, Cotton DJ, et al: Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 330:738-743, 1994
11. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991